Free
Critical Care Medicine  |   July 2014
Inhibition of the Ubiquitin–Proteasome Pathway Does Not Protect against Ventilator-induced Accelerated Proteolysis or Atrophy in the Diaphragm
Author Affiliations & Notes
  • Ashley J. Smuder, Ph.D.
    From the Department of Applied Physiology and Kinesiology, Center for Exercise Science, University of Florida, Gainesville, Florida (A.J.S., S.K.P.); Division of Mathematics, Computer, and Natural Sciences, Department of Natural Sciences, Ohio Dominican University, Columbus, Ohio (W.B.N.); Department of Medicine, Emory University, Atlanta, Georgia (M.B.H.); and School of Kinesiology, Auburn University, Auburn, Alabama (A.N.K.).
  • W. Bradley Nelson, Ph.D.
    From the Department of Applied Physiology and Kinesiology, Center for Exercise Science, University of Florida, Gainesville, Florida (A.J.S., S.K.P.); Division of Mathematics, Computer, and Natural Sciences, Department of Natural Sciences, Ohio Dominican University, Columbus, Ohio (W.B.N.); Department of Medicine, Emory University, Atlanta, Georgia (M.B.H.); and School of Kinesiology, Auburn University, Auburn, Alabama (A.N.K.).
  • Matthew B. Hudson, Ph.D.
    From the Department of Applied Physiology and Kinesiology, Center for Exercise Science, University of Florida, Gainesville, Florida (A.J.S., S.K.P.); Division of Mathematics, Computer, and Natural Sciences, Department of Natural Sciences, Ohio Dominican University, Columbus, Ohio (W.B.N.); Department of Medicine, Emory University, Atlanta, Georgia (M.B.H.); and School of Kinesiology, Auburn University, Auburn, Alabama (A.N.K.).
  • Andreas N. Kavazis, Ph.D.
    From the Department of Applied Physiology and Kinesiology, Center for Exercise Science, University of Florida, Gainesville, Florida (A.J.S., S.K.P.); Division of Mathematics, Computer, and Natural Sciences, Department of Natural Sciences, Ohio Dominican University, Columbus, Ohio (W.B.N.); Department of Medicine, Emory University, Atlanta, Georgia (M.B.H.); and School of Kinesiology, Auburn University, Auburn, Alabama (A.N.K.).
  • Scott K. Powers, Ph.D., Ed.D.
    From the Department of Applied Physiology and Kinesiology, Center for Exercise Science, University of Florida, Gainesville, Florida (A.J.S., S.K.P.); Division of Mathematics, Computer, and Natural Sciences, Department of Natural Sciences, Ohio Dominican University, Columbus, Ohio (W.B.N.); Department of Medicine, Emory University, Atlanta, Georgia (M.B.H.); and School of Kinesiology, Auburn University, Auburn, Alabama (A.N.K.).
  • Submitted for publication May 15, 2013. Accepted for publication February 27, 2014.
    Submitted for publication May 15, 2013. Accepted for publication February 27, 2014.×
  • Address correspondence to Dr. Smuder: Department of Applied Physiology and Kinesiology, University of Florida, Room 25 Florida Gym, Gainesville, Florida 32611. asmuder@ufl.edu. Information on purchasing reprints may be found at www.anesthesiology.org or on the masthead page at the beginning of this issue. Anesthesiology’s articles are made freely accessible to all readers, for personal use only, 6 months from the cover date of the issue.
Article Information
Critical Care Medicine / Basic Science / Critical Care / Respiratory System
Critical Care Medicine   |   July 2014
Inhibition of the Ubiquitin–Proteasome Pathway Does Not Protect against Ventilator-induced Accelerated Proteolysis or Atrophy in the Diaphragm
Anesthesiology 07 2014, Vol.121, 115-126. doi:10.1097/ALN.0000000000000245
Anesthesiology 07 2014, Vol.121, 115-126. doi:10.1097/ALN.0000000000000245
Abstract

Background: Mechanical ventilation (MV) is a life-saving intervention in patients with acute respiratory failure. However, prolonged MV results in ventilator-induced diaphragm dysfunction (VIDD), a condition characterized by both diaphragm fiber atrophy and contractile dysfunction. Previous work has shown that calpain, caspase-3, and the ubiquitin–proteasome pathway (UPP) are all activated in the diaphragm during prolonged MV. However, although it is established that both calpain and caspase-3 are important contributors to VIDD, the role that the UPP plays in the development of VIDD remains unknown. These experiments tested the hypothesis that inhibition of the UPP will protect the diaphragm against VIDD.

Methods: The authors tested this prediction in an established animal model of MV using a highly specific UPP inhibitor, epoxomicin, to prevent MV-induced activation of the proteasome in the diaphragm (n = 8 per group).

Results: The results of this study reveal that inhibition of the UPP did not prevent ventilator-induced diaphragm muscle fiber atrophy and contractile dysfunction during 12 h of MV. Also, inhibition of the UPP does not affect MV-induced increases in calpain and caspase-3 activity in the diaphragm. Finally, administration of the proteasome inhibitor did not protect against the MV-induced increases in the expression of the E3 ligases, muscle ring finger-1 (MuRF1), and atrogin-1/MaFbx.

Conclusion: Collectively, these results indicate that proteasome activation does not play a required role in VIDD development during the first 12 h of MV.

Pharmacologic inhibition of the ubiquitin–proteasome pathway, using epoxomicin, did not protect the diaphragm against oxidative stress or atrophy in anesthetized, mechanically ventilated rats.

What We Already Know about This Topic
  • Mechanical ventilation is associated with rapid development of atrophy of the diaphragm, which contributes to respiratory failure

What This Article Tells Us That Is New
  • Pharmacologic inhibition of the ubiquitin–proteasome pathway, using epoxomicin, did not protect the diaphragm against oxidative stress or atrophy in anesthetized, mechanically ventilated rats

MECHANICAL ventilation (MV) is used in critical care medicine to maintain adequate alveolar ventilation in patients. Common indications for MV include pulmonary disorders, heart failure, neuromuscular diseases, coma, and surgery. Although MV can be a life-saving intervention, prolonged MV results in the rapid development of ventilator-induced diaphragm dysfunction (VIDD) which occurs due to diaphragm atrophy and contractile dysfunction.1–3  From a clinical perspective, VIDD is important because respiratory muscle weakness is predicted to contribute to difficulties in weaning patients from the ventilator.4  However, there is currently no drug therapy or clinical standard of care to address this problem. Therefore, improving our understanding of the processes that promote VIDD is essential to develop a therapeutic strategy to prevent MV-induced diaphragm weakness. In this regard, we determined whether targeting the ubiquitin–proteasome pathway (UPP) via epoxomicin administration is sufficient to protect against VIDD. The clinical importance of VIDD and the rationale supporting our approach are further highlighted in the next section.
The development of VIDD occurs rapidly and has been reported to occur within 12 to 18 h after the initiation of MV.1,2  Reports indicate that approximately 33% of all adult patients admitted to an intensive care unit require MV, and weaning procedures account for 40 to 50% of the total time spent in the critical care unit.5  Although numerous factors can contribute to weaning difficulties, the most frequent cause of weaning failure in patients is inspiratory (i.e., diaphragm) muscle weakness. Therefore, developing strategies to prevent VIDD is clinically important. Previous work reveals that MV-induced diaphragm atrophy occurs due to both decreased protein synthesis and increased proteolysis.3,6,7  However, because of the rapid development of VIDD, MV-induced increases in diaphragm protein breakdown seem to play the dominant role.3  In regard to MV-induced proteolysis, all four primary proteolytic systems are activated in the diaphragm during MV, including calpain, caspase-3, autophagy, and the UPP.3,8,9  However, only calpain and caspase-3 have been shown to participate in the development of VIDD and the role that autophagy and the UPP play remains unknown.9–11  The absence of studies investigating the role of the UPP in the development of VIDD is surprising, given that the UPP is considered to be an important proteolytic system responsible for the breakdown of myofibrillar proteins and the UPP plays a required role in inactivity-induced atrophy in limb skeletal muscles.12  In this regard, a recent study by Agten et al.13  administered the protease inhibitor bortezomib to animals during prolonged MV in an attempt to elucidate the role that the UPP plays in the development of VIDD. However, bortezomib inhibited caspase-3 activation but did not inhibit the MV-induced increase in 20S proteasome activity in the diaphragm. Thus, additional work is needed to determine the contribution of UPP to VIDD and thus forms the basis for the current experiments. Therefore, these experiments tested the hypothesis that pharmacological inhibition of the UPP will protect the diaphragm against VIDD.
Materials and Methods
Experimental Design
Young adult female Sprague–Dawley rats were used in these experiments. Animals were assigned to one of three experimental groups (n = 8 per group): (1) acutely anesthetized control animals (CON); (2) 12-h mechanically ventilated animals, no treatment (MV); and (3) 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin). The Institutional Animal Care and Use Committee of the University of Florida (Gainesville, Florida) approved these experiments. In an effort to comply with the U.S. Animal Welfare Act and Public Health Service Policy by using the absolute minimum number of animals required to achieve the science, measurements made using the control and MV groups were also used in a previously published article.11  Investigators were blinded during the analysis of the data when possible (diaphragm contractile force and cross-sectional area).
Acutely Anesthetized Controls
Control animals were acutely anesthetized with an intraperitoneal injection of sodium pentobarbital (100 mg/kg body weight). After reaching a surgical plane of anesthesia, the diaphragm was quickly removed and the costal diaphragm was divided into several segments. One strip of the medial costal diaphragm was stored for histological measurements, another strip was immediately used for specific force measurements, and the remaining portion of the costal diaphragm was rapidly frozen in liquid nitrogen and stored at −80°C for subsequent biochemical analyses.
Mechanical Ventilation
All surgical procedures were performed using aseptic techniques. Animals in the MV groups were anesthetized with an intraperitoneal injection of sodium pentobarbital (60 mg/kg body weight). Animals were then tracheostomized, and mechanically ventilated with a pressure-controlled ventilator (Servo Ventilator 300; Siemens AG, Munich, Germany) for 12 h with the following settings: upper airway pressure limit, 20 cm H2O; respiratory rate, 80 breaths/min; and positive end-expiratory pressure, 1 cm H2O. Previous work by our laboratory has demonstrated that the full support mode of MV used in this study results in the complete cessation of inspiratory electromyogram activity in the diaphragm.2 
The carotid artery was cannulated to permit the continuous measurement of blood pressure and the collection of blood during the protocol. Arterial blood samples (150 μl per sample) were removed periodically and analyzed for arterial partial pressure of oxygen, carbon dioxide, and pH using an electronic blood gas analyzer (GEM Premier 3000; Instrumentation Laboratory, Lexington, MA). Ventilator adjustments were made if arterial partial pressure of oxygen exceeded 40 to 45 mmHg. Moreover, arterial partial pressure of oxygen was maintained greater than 60 mmHg throughout the experiment by increasing the Fio2 (22 to 27%). A venous catheter was inserted into the jugular vein for continuous infusion of sodium pentobarbital (10 mg/kg of body weight per hour).
Body temperature was maintained at 37°C by use of a recirculating water heating blanket, and heart rate was monitored via a lead II electrocardiograph. Continuous care during the MV protocol included lubricating the eyes, expressing the bladder, removing airway mucus, rotating the animal, and passively moving the limbs. Animals also received an intramuscular injection of glycopyrrolate (0.04 mg/kg of body weight) every 2 h during MV to reduce airway secretions. On completion of MV, the diaphragm was quickly removed and a section was stored for histochemical analyses, another strip was immediately used for contractile measurements, and the remaining portion was frozen in liquid nitrogen and stored at −80°C for subsequent biochemical analyses.
Proteasome Inhibition
To prevent MV-induced proteasome activation in the diaphragm, we administered the highly selective proteasome inhibitor, namely epoxomicin (0.55 μg/kg body weight) (Boston Biochem, Boston, MA). This dose was chosen based on previous reports demonstrating the effectiveness of this dose14  and the efficacy of this dose was confirmed in our preliminary experiments. The inhibitor was dissolved in 60% dimethyl sulfoxide and given intravenously as a bolus immediately before the initiation of MV. Importantly, preliminary work demonstrated that the use of dimethyl sulfoxide as the vehicle had no additional effects on diaphragm contractile dysfunction after 12 h of MV (table 1).
Table 1.
Effects of DMSO Administration on Diaphragm Contractile Function
Effects of DMSO Administration on Diaphragm Contractile Function×
Image Not Available
Table 1.
Effects of DMSO Administration on Diaphragm Contractile Function
Effects of DMSO Administration on Diaphragm Contractile Function×
×
Measurement of In Vitro Diaphragm Contractile Properties
On sacrifice or the completion of the MV period, the entire diaphragm was removed and placed in a dissecting chamber containing a Krebs–Hensleit solution equilibrated with 95% O2–5% CO2 gas. A muscle strip, including the tendinous attachments at the central tendon and rib cage was dissected from the midcostal region. The strip was suspended vertically between two lightweight Plexiglas clamps with one end connected to an isometric force transducer (model FT-03; Grass Instruments, Quincy, MA) within a jacketed tissue bath. The force output was recorded via a computerized data-acquisition system (Super Scope II; GW Instruments, Somerville, MA; Apple Computer, Cupertino, CA). Lo (i.e., the length at which peak twitch tension is achieved) was determined by systematically adjusting the length of the muscle using a micrometer while evoking single twitches. Thereafter, all contractile properties were measured isometrically at Lo. To measure maximal isometric twitch force, each strip was stimulated supramaximally with 120-V pulses at 1 Hz, and to measure the force–frequency response, each strip was stimulated supramaximally with 120-V pulses at 15 to 160 Hz. The duration of each train was 500 ms to achieve a force plateau. Contractions were separated by a 2-min recovery period. For comparative purposes, diaphragmatic (bundles of fibers) force production was normalized as specific Po. The total muscle cross-sectional area at right angles to the long axis was calculated by using the following algorithm15 : Total muscle cross-sectional area (mm2) = [muscle mass/(fiber length × 1.056)], where 1.056 is the density of muscle (in g/cm3). Fiber length was expressed in centimeters measured at Lo.16 
Myofiber Cross-sectional Area
Sections from frozen diaphragm samples were cut at 10 μm thickness using a cryotome (Shandon Inc., Pittsburgh, PA) and stained as described previously.9  Cross-sectional area was determined using Scion software (National Institutes of Health, Bethesda, MD).
Myofibrillar Protein Isolation and Release
Myofibrillar protein isolation and easily releasable myofilament protein assay were performed with a previously described protocol.17,18  The final supernatant containing the released myofilaments was collected, and the pellet containing the residual myofibrillar protein fraction was resuspended. Proteins from both fractions were then assayed by the Bradford method (Sigma-Aldrich, St. Louis, MO). Myofibrillar protein (released myofibrillar protein + intact myofibrillar protein) was then corrected for muscle weight and expressed as myofibrillar protein concentration (microgram myofibrillar protein/milligram diaphragm muscle). Released myofilaments were expressed as a percentage of the combined amount of protein in the two fractions.
Western Blot Analysis
Protein abundance was determined in diaphragm samples via Western blot analysis. In brief, diaphragm tissue samples were homogenized 1:10 (wt/vol) in 5 mM Tris (pH 7.5) and 5 mM EDTA (pH 8.0) with a protease inhibitor cocktail (Sigma-Aldrich) and centrifuged at 1,500g for 10 min at 4°C. After collecting the resulting supernatant, diaphragm protein content was assessed by the method of Bradford (Sigma-Aldrich). Proteins from the supernatant fraction were separated via polyacrylamide gel electrophoresis. Proteins were transferred to nitrocellulose membranes, blocked in 5% nonfat milk, and incubated with primary antibodies directed against proteins of interest. 4-hydroxynonenal (4-HNE) (Abcam, Cambridge, MA), poly-ubiqutinated proteins (pUB) (Boston Biochem), active calpain (Cell Signaling, Beverly, MA), cleaved caspase-3 (Cell Signaling), spectrin (Santa Cruz, Santa Cruz, CA), muscle ring finger-1 (MuRF1) (ECM Biosciences, Versailles, KY), and atrogin-1 (ECM Biosciences) were assessed. Finally, tubulin (Santa Cruz) protein content was measured to normalize for equal protein loading and transfer. Membranes were developed using autoradiographic film and images of the film were captured and analyzed using the 440CF Kodak Imaging System (Kodak, New Haven, CT).
RNA Isolation and Complementary DNA Synthesis
Total RNA was isolated from muscle tissue with TRIzol Reagent (Life Technologies, Carlsbad, CA) according to the manufacturer’s instructions. RNA content (microgram per milligram muscle weight) was evaluated by spectrophotometry. RNA (5 μg) was then reverse transcribed with the Superscript III First-Strand Synthesis System for reverse transcription-polymerase chain reaction (Life Technologies), using oligo(dT)20 primers and the protocol outlined by the manufacturer.
Real-time Polymerase Chain Reaction
One microliter of complementary DNA was added to a 25 μl of polymerase chain reaction mixture for real-time polymerase chain reaction using Taqman chemistry and the ABI Prism 7000 Sequence Detection system (ABI, Foster City, CA). Relative quantification of gene expression was performed using the comparative computed tomography method (ABI, User Bulletin No. 2). β-Glucuronidase, a lysosomal glycoside hydrolase, was chosen as the reference gene based on previous work showing unchanged expression with our experimental interventions.19,20  MuRF1 and atrogin-1/MaFbx microRNA transcripts were assayed using predesigned rat primer and probe sequences commercially available from ABI (Assays-on-Demand).
20S Proteasome Activity Assay
A section of the ventral costal diaphragm was homogenized 1:10 (vol: vol) in 5 mM Tris-HCL (pH 7.5) and 5 mM EDTA (pH 8.0) and centrifuged at 1,500g for 10 min at 4°C. The cytosolic fraction was centrifuged at 10,000g for 10 min at 4°C, followed by an additional spin of the supernatant at 100,000g for 1 h at 4°C. The in vitro chymotrypsin-like activity of the 20S proteasome was measured fluorometrically using the techniques described in the study by Stein et al.21 
Statistical Analysis
In vitro diaphragmatic specific force production was analyzed using a two-way mixed design group × frequency (3 × 5) ANOVA with repeated measures on frequency. Follow-up tests were conducted using the Bonferroni procedure. For the data on cross-sectional area, we compared the groups at each fiber type (i.e., I, IIa, and IIx/IIb) with one-way ANOVAs. Data for 4-HNE, easily releasable myofilaments, MuRF1, atrogin-1, pUB, 20S proteasome activity, calpain, spectrin breakdown product 145 kDa, caspase-3, and spectrin breakdown product 120 kDa were compared between groups by one-way ANOVA. When the one-way ANOVAs revealed statistically significant differences, a conservative Bonferroni adjustment was performed to identify group differences. Physiological variables (i.e., heart rate, systolic blood pressure, arterial partial pressure of oxygen and carbon dioxide, and arterial pH) were compared using the independent t test. Data points 2SDs different from the average were removed from the analyses. All statistical comparisons were performed using two-tailed tests. Overall significance was established at P value less than 0.05 and adjusted (i.e., P = 0.05/3 = 0.0167) with Bonferroni technique when examining the group main effect means. Data are presented as mean ± SD. All statistical analyses were performed using PASW Statistics 21 (SPSS, Inc., Chicago, IL).
Results
Systemic and Biologic Response to MV
Before the initiation of MV, no significant differences existed in body weight between the experimental groups. Importantly, 12 h of MV did not significantly alter body weight between groups (data not shown). In addition, heart rate and systolic blood pressure were maintained relatively constant during the 12 h of MV, and no significant differences existed between experimental groups in any of these measures at the completion of 12 h of MV (table 2). The arterial partial pressures of oxygen and carbon dioxide and pH were also maintained relatively constant during MV with no significant differences existing between groups (table 2). In addition, the colonic (body) temperature was homeostatic and relatively constant (36° to 37°C) during the MV period. At the completion of the MV protocol, there were no visual abnormalities of the lungs or peritoneal cavity, no visible indication of lung injury, and no evidence of infection, indicating that our aseptic surgical technique was successful.
Table 2.
Systemic and Biological Response to MV
Systemic and Biological Response to MV×
Image Not Available
Table 2.
Systemic and Biological Response to MV
Systemic and Biological Response to MV×
×
Epoxomicin Partially Protects against MV-induced Diaphragm Contractile Dysfunction
To determine the role of the UPP in MV-induced diaphragm contractile dysfunction, we measured the in vitro specific force generation of diaphragm muscle strips. Similar to published reports, 12 h of MV resulted in a significant decrease in specific force generation.2,22,23  Animals treated with epoxomicin were partially protected against MV-induced diaphragm contractile dysfunction. However, diaphragmatic specific force production in the MV + epoxomicin group remained significantly lower compared with that in control animals (fig. 1).
Fig. 1.
Diaphragmatic force–frequency response (in vitro). Values are mean ± SD (n = 8 per group). CON significantly different versus mechanical ventilation (MV) (P < 0.001); CON significantly different versus MV + epoxomicin (P < 0.001); MV significantly different versus MV + epoxomicin (P = 0.007). Acutely anesthetized control animals (CON); 12-h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
Image Not Available
Fig. 1.
Diaphragmatic force–frequency response (in vitro). Values are mean ± SD (n = 8 per group). CON significantly different versus mechanical ventilation (MV) (P < 0.001); CON significantly different versus MV + epoxomicin (P < 0.001); MV significantly different versus MV + epoxomicin (P = 0.007). Acutely anesthetized control animals (CON); 12-h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
×
Epoxomicin Administration Does Not Prevent MV-induced Diaphragm Atrophy
To determine whether the UPP is required for MV-induced diaphragm atrophy, we measured the cross-sectional area of diaphragm myofibers after 12 h of MV. Our results demonstrate that compared with control, MV promotes significant atrophy in fiber type I in diaphragm muscle. Importantly, our data also reveal that inhibition of the 20S proteasome does not prevent this MV-induced diaphragm atrophy (fig. 2).
Fig. 2.
Fiber cross-sectional area in diaphragm skeletal muscle myofibers expressing myosin heavy chain (MHC) I (type I), MHC IIa (type IIa), and MHC IIx/IIb (type IIx/IIb) (CON: n = 7; MV: n = 8; MV + epoxomicin: n = 8). Values are mean ± SD. *Significantly different versus CON (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12-h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
Image Not Available
Fig. 2.
Fiber cross-sectional area in diaphragm skeletal muscle myofibers expressing myosin heavy chain (MHC) I (type I), MHC IIa (type IIa), and MHC IIx/IIb (type IIx/IIb) (CON: n = 7; MV: n = 8; MV + epoxomicin: n = 8). Values are mean ± SD. *Significantly different versus CON (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12-h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
×
Epoxomicin Does Not Affect MV-induced Oxidative Damage in Diaphragm
Oxidative stress has been linked to accelerated rates of proteolysis and diaphragm atrophy during prolonged MV.7,24  4-HNE is formed during the lipid peroxidation cascade and measurement of 4-HNE–modified protein adducts is an excellent biomarker of oxidative damage in muscle. In this regard, MV resulted in a significant increase in the accumulation of 4-HNE–modified proteins in the diaphragm. However, treatment of animals with epoxomicin failed to inhibit the increase in MV-induced oxidative damage in the diaphragm (fig. 3).
Fig. 3.
The levels of 4-hydroxynonenal (4-HNE). A representative blot for 4-HNE protein conjugates is shown above the graph. Values are mean percentage change ± SD (n = 8 per group). *Significantly different versus CON (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
Image Not Available
Fig. 3.
The levels of 4-hydroxynonenal (4-HNE). A representative blot for 4-HNE protein conjugates is shown above the graph. Values are mean percentage change ± SD (n = 8 per group). *Significantly different versus CON (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
×
Epoxomicin Fails to Prevent Diaphragm Myofibrillar Protein Release
Easily releasable myofilaments were measured as an index of sarcomeric protein release in the diaphragm during MV. Our results reveal that MV produces a significant increase in the percentage of easily releasable myofibrillar proteins in the diaphragm and that inhibiting the 20S proteasome with epoxomicin does not attenuate this release of sarcomeric proteins from the myofibrillar lattice (fig. 4).
Fig. 4.
Easily releasable myofilaments (CON: n = 7; MV: n = 8; MV + epoxomicin: n = 7). Values are mean percentage change ± SD. *Significantly different versus CON (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
Image Not Available
Fig. 4.
Easily releasable myofilaments (CON: n = 7; MV: n = 8; MV + epoxomicin: n = 7). Values are mean percentage change ± SD. *Significantly different versus CON (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
×
Epoxomicin Does Not Prevent MV-induced Diaphragmatic Expression of MuRF1 and Atrogin-1/MaFbx
During periods of inactivity, the UPP relies on E3 ubiquitin ligases to tag damaged and misfolded muscle proteins, targeting them for degradation. To determine whether inhibition of the 20S proteasome affects muscle E3 ligase expression, we measured the microRNA expression and protein abundance of MuRF1 and atrogin-1/MaFbx. Compared with control, 12 h of MV significantly increased the expression of both MuRF1 and atrogin-1/MaFbx in the diaphragm. However, proteasome inhibition did not prevent the MV-induced increases in the protein expression of either MuRF1 or atrogin-1/MaFbx. However, epoxomicin treatment did result in a significant reduction in MuRF1 microRNA expression compared with MV (fig. 5, A–D). In addition to MuRF1 and atrogin-1/MaFbx, the presence of ubiquitinated proteins can serve as a marker of proteasome activity and changes in protein turnover. Therefore, we measured the levels of ubiquitinated proteins in the diaphragm to determine whether epoxomicin inhibited the formation of poly-ubiquitinated protein conjugates. Our results demonstrate that treatment of MV animals with epoxomicin results in a significant increase in ubiquitin protein concentration in the diaphragm (fig. 6A).
Fig. 5.
(A) microRNA (mRNA) levels of muscle ring finger-1 (MuRF1) (CON: n = 8; MV: n = 7; MV + epoxomicin: n = 7). (B) mRNA levels of atrogin-1/Muscle Atrophy F-box (MaFbx) (CON: n = 8; MV: n = 8; MV + epoxomicin: n = 7). (C) Protein levels for MuRF1 (CON: n = 8; MV: n = 7; MV + epoxomicin: n = 8). (D) Protein levels for atrogin-1/MaFbx (n = 8 per group). Representative blots for MuRF1 and atrogin-1/MaFbx protein are shown above the graph. Values are mean percentage change ± SD. *Significantly different versus CON (P < 0.0167). §Significantly different versus CON and MV + epoxomicin (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
Image Not Available
Fig. 5.
(A) microRNA (mRNA) levels of muscle ring finger-1 (MuRF1) (CON: n = 8; MV: n = 7; MV + epoxomicin: n = 7). (B) mRNA levels of atrogin-1/Muscle Atrophy F-box (MaFbx) (CON: n = 8; MV: n = 8; MV + epoxomicin: n = 7). (C) Protein levels for MuRF1 (CON: n = 8; MV: n = 7; MV + epoxomicin: n = 8). (D) Protein levels for atrogin-1/MaFbx (n = 8 per group). Representative blots for MuRF1 and atrogin-1/MaFbx protein are shown above the graph. Values are mean percentage change ± SD. *Significantly different versus CON (P < 0.0167). §Significantly different versus CON and MV + epoxomicin (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
×
Fig. 6.
(A) Protein levels for poly-ubiquitinated protein (pUB) (n = 8 per group). (B) Chymotrypsin-like activity of the 20S ubiquitin–proteasome system (n = 7 per group). Representative blots for pUB protein are shown above the graph. Values are mean percentage change ± SD. *Significantly different versus CON (P < 0.0167). §Significantly different versus CON and MV + epoxomicin (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
Image Not Available
Fig. 6.
(A) Protein levels for poly-ubiquitinated protein (pUB) (n = 8 per group). (B) Chymotrypsin-like activity of the 20S ubiquitin–proteasome system (n = 7 per group). Representative blots for pUB protein are shown above the graph. Values are mean percentage change ± SD. *Significantly different versus CON (P < 0.0167). §Significantly different versus CON and MV + epoxomicin (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
×
Epoxomicin Selectively Inhibits Proteasome Activity In Vivo
To verify that epoxomicin was effective in preventing proteasome activity, we measured the chymotrypsin-like activity of the 20S proteasome in the diaphragm. Importantly, our results verified that administration of epoxomicin prevents the MV-induced increase in 20S proteasome activity in the diaphragm (fig. 6B).
Epoxomicin Does Not Prevent Calpain or Caspase-3 Protease Activation
Given that previous work has shown both calpain and caspase-3 are required for VIDD,9–11  we determined whether diaphragmatic calpain and/or caspase-3 activity was inhibited by epoxomicin. Similar to previous results, we report that the protein abundance of active calpain-1 and the abundance of the 145-kDa calpain-specific spectrin breakdown product were significantly increased after 12 h of MV in the diaphragm and treatment with epoxomicin did not attenuate this increase in calpain activity (fig. 7). In addition, we measured cleaved (active) caspase-3 and the 120-kDa caspase-specific spectrin breakdown product as markers of caspase-3 activity. MV resulted in a significant increase in caspase-3 activity in the diaphragm and this activity remained increased in MV animals treated with epoxomicin (fig. 8).
Fig. 7.
Calpain activation in the diaphragm was determined via Western blot. (A) Active calpain-1 (n = 8 per group). (B) Calpain-specific spectrin breakdown product (SBDP) (n = 8 per group). Representative Western blots are shown above the graphs. Values are mean percentage change ± SD. *Significantly different versus CON (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
Image Not Available
Fig. 7.
Calpain activation in the diaphragm was determined via Western blot. (A) Active calpain-1 (n = 8 per group). (B) Calpain-specific spectrin breakdown product (SBDP) (n = 8 per group). Representative Western blots are shown above the graphs. Values are mean percentage change ± SD. *Significantly different versus CON (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
×
Fig. 8.
Caspase-3 activation in the diaphragm was determined via Western blot. (A) Cleaved (active) caspase-3 (CON: n = 8; MV: n = 6; MV + epoxomicin: n = 6). (B) Caspase-3-specific spectrin breakdown product (SBDP) (n = 8 per group). Representative Western blots are shown above the graphs. Values are mean percentage change ± SD. *Significantly different versus CON (P< 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
Image Not Available
Fig. 8.
Caspase-3 activation in the diaphragm was determined via Western blot. (A) Cleaved (active) caspase-3 (CON: n = 8; MV: n = 6; MV + epoxomicin: n = 6). (B) Caspase-3-specific spectrin breakdown product (SBDP) (n = 8 per group). Representative Western blots are shown above the graphs. Values are mean percentage change ± SD. *Significantly different versus CON (P< 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
×
Discussion
Overview of Principal Findings
Our results reveal that inhibition of 20S proteasome activity is not sufficient to protect the diaphragm against MV-induced diaphragm fiber atrophy, but inhibition of 20S activity does provide partial protection against MV-induced diaphragmatic contractile dysfunction. A detailed discussion of these findings follows.
UPP Activation Is Not a Major Contributor to VIDD during 12 h of MV
The ubiquitin–proteasome system is a key proteolytic system in muscle fibers that plays an important role during muscle wasting.25–27  The total proteasome complex (26S) is comprised a core proteasome subunit (20S) coupled with two regulatory complexes (19S).28,29  The primary function of this system is to degrade proteins that have been poly-ubiquitinated. In this regard, previous work from our laboratory suggests that proteolytic processing by the UPP is increased in the diaphragm during prolonged MV.30  However, the contribution of this pathway to VIDD remains unknown. Historically, the UPP has been characterized as the dominant proteolytic pathway in disuse muscle atrophy.26,31  Therefore, we investigated the role that the UPP plays in MV-induced diaphragm atrophy using the 20S proteasome inhibitor epoxomicin. Our results reveal that treatment of mechanically ventilated animals with epoxomicin partially attenuates the MV-induced decrease in diaphragm contractile force production, but does not protect against MV-induced diaphragmatic fiber atrophy. Our interpretation of these findings is that although the UPP is active during MV, this proteolytic system does not play a dominant role in the development of VIDD during the first 12 h of MV.
Proteasome Inhibition Does Not Affect MV-induced Oxidative Damage in the Diaphragm
Protein oxidation can promote protein recognition and degradation by many proteolytic systems (i.e., calpain, caspase-3, and UPP). Indeed, previous work has demonstrated that protein oxidation can enhance proteins susceptibility to degradation by altering the proper folding of proteins resulting in increased recognition and proteolysis of damaged proteins.29,32,33  Regulatory proteins that influence force production include actin, myosin, tropomyosin, and the troponin complex (reviewed in the study by Smith and Reid34 ). Each of these proteins seems to be sensitive to oxidation and, therefore, to modifications that diminish force production, rendering them potential targets for proteolytic degradation.29,32,34  In addition to oxidative modification of myofibrillar proteins, reports indicate that oxidative stress promotes the increased expression of proteins necessary for UPP function. Specifically, exposure of myotubes to hydrogen peroxide is sufficient to increase the expression of specific ubiquitin ligases.35–37  Therefore, increased reactive oxygen species production seems to promote muscle protein degradation via the UPP. In this regard, we measured the abundance of 4-HNE–modified proteins to determine whether inhibition of 20S proteasome activity results in a reduction of MV-induced oxidative damage in the diaphragm. In agreement with numerous reports, our results confirm that prolonged MV increases diaphragmatic oxidative stress,7,22,38  and treatment of animals with epoxomicin does not attenuate the MV-induced accumulation of 4-HNE in the diaphragm.
MV-induced Activation of Diaphragm Proteases
Mechanical ventilation–induced diaphragm atrophy results from an imbalance in the rate of muscle protein synthesis and degradation, with increased protein degradation playing the dominant role.39,40  In this regard, myofibrillar proteins constitute 50 to 60% of muscle protein and are degraded at a faster rate than other classes of muscle proteins during disuse muscle atrophy.41  In addition, myofibrillar proteins have also been shown to be the principal protein target of the UPP.42  The degradation of myofibrillar proteins is a process that requires the coordination of several proteolytic systems, including the calpain, caspase-3, and the UPP. Specifically, it is predicted that the UPP is unable to cleave intact sarcomeric proteins, and that release of these myofilaments from the sarcomeric lattice is required for UPP degradation of actin and myosin.40,43 
As discussed previously, the breakdown of muscle proteins by the UPP requires ubiquitination of the targeted proteins. This poly-ubiquitination is a three-step process in which activation of specific protein ligases leads to the activation and conjugation of ubiquitin to protein substrates followed by the degradation of poly-ubiquitin-tagged proteins by the proteasome. Specifically, ubiquitin monomers are activated by E1 or ubiquitin-activating proteins and transferred to E2 ubiquitin-conjugating proteins. Finally, in coordination with the E3 ligases, ubiquitin is attached to the protein substrate.44  In reference to substrate recognition and degradation, expression of E2 and E3 ligases determines the specificity of the UPP and transcriptional levels of these proteins strongly correlates with muscle catabolism.40,43,44  Furthermore, expression of the muscle-specific E3 ligases MuRF1 and atrogin-1/MaFbx has been reported to be essential for skeletal muscle atrophy.25–27  Similarly, Bodine et al.26  demonstrated that these ligases are critical regulators of muscle atrophy and the deletion of either ligase during denervation is sufficient to protect muscle size and/or mass.
Although the importance of both MuRF1 and atrogin-1/MaFbx has been demonstrated in other models of disuse muscle atrophy, the role that these ligases play in VIDD remains unknown. In regard to E3 ligase expression, the current results demonstrate that 12 h of MV is sufficient to increase the transcription of both MuRF1 and atrogin-1/MaFbx in the diaphragm.22,23  However, treatment of mechanically ventilated animals with epoxomicin did not reduce the expression of these E3 ligases in the diaphragm. Our data also demonstrate that 12 h of MV increases protein ubiquitination in the diaphragm and the levels of ubiquitinated proteins in the diaphragm tended to be higher in the MV animals treated with epoxomicin. This increased protein ubiquitination in MV animals is likely due to an accumulation of poly-ubiquitinated proteins resulting from increased MuRF1 and atrogin-1/MaFbx in the diaphragm. Furthermore, the increase in ubiquitinated proteins in the diaphragms of MV animals treated with epoxomicin is expected because these tagged proteins cannot be degraded by the UPP because of epoxomicin-induced inhibition of 20S proteasome activity.
Finally, although it has been proposed that the UPP is the primary proteolytic system essential for the degradation of myofibrillar proteins, it has also been demonstrated that the activity of other proteases play an obligatory role in diaphragm protein breakdown during prolonged MV.7,9–11  Specifically, calpain and caspase-3 activation both seem to play a required role in MV-induced diaphragm muscle turnover.9–11  In this regard, it has been hypothesized that actomyosin complexes and other myofilaments must first be released from the sarcomere, unfolded and ubiquitinated for UPP degradation.45–49  This suggests that the rate-limiting step in muscle contractile protein degradation is the processing required for UPP proteolysis. Furthermore, evidence indicates that both calpain and caspase-3 can promote actomyosin disassociation.45,49,50  Therefore, it has been speculated that activation of calpain and caspase-3 is required for UPP degradation of myofibrillar proteins.32,50  A long-standing rationale for the prediction that the UPP is essential for disuse muscle atrophy is that the two major contractile proteins actin and myosin are reported to be weak substrates for calpain and caspase-3.45  However, recent evidence indicates that oxidized myofibrillar proteins can be directly degraded by both calpain and caspase-3 which demonstrates that the UPP may not be required for the degradation of myofibrillar proteins in skeletal muscles exposed to oxidative stress.32  Indeed, work from our laboratory demonstrates that prolonged MV results in oxidation of both actin and myosin in the diaphragm and that oxidation greatly increases the susceptibility of actin and myosin along with other skeletal muscle myofibrillar proteins to degradation by calpain and caspase-3.32,51  Therefore, during prolonged MV where myofibrillar proteins in the diaphragm are exposed to oxidizing conditions, activation of the UPP system may not be required for the rapid atrophy that occurs within the first 12 h of prolonged MV.
Conclusions
This study provides the first evidence that the UPP plays a limited role in the development of VIDD during the first 12 h of MV. Indeed, although the UPP is activated in the diaphragm during MV, inhibition of 20S proteasome activity is not sufficient to protect the diaphragm against MV-induced contractile dysfunction and atrophy during the first 12 h of MV. Therefore, these results along with previous reports suggest that activation of calpain and caspase-3 plays a key role in the development of VIDD.32,45,50  Hence, although the proteasome has been considered to be the primary protease responsible for myofibrillar protein degradation during locomotor muscle atrophy, its contribution to VIDD during the first 12 h of ventilator support seems to be limited. In regard to the impact of epoxomicin on diaphragm contractile function at high stimulation frequencies, it is feasible that the autophagy/lysosomal system can degrade poly-ubiquitinated proteins. Therefore, it is possible that activation of the autophagy/lysosomal system is upregulated in when UPP activity is inhibited. This is a testable hypothesis that is worthy of future experimentation.
Acknowledgments
This work was supported by the National Institutes of Health (Bethesda, Maryland) award (RO1 HL780839; to S.K.P.).
Competing Interests
The authors declare no competing interests.
References
1.Levine, S, Nguyen, T, Taylor, N, Friscia, ME, Budak, MT, Rothenberg, P, Zhu, J, Sachdeva, R, Sonnad, S, Kaiser, LR, Rubinstein, NA, Powers, SK, Shrager, JB Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans.. N Engl J Med. (2008). 358 1327–35 [Article] [PubMed]
1.Levine, S, Nguyen, T, Taylor, N, Friscia, ME, Budak, MT, Rothenberg, P, Zhu, J, Sachdeva, R, Sonnad, S, Kaiser, LR, Rubinstein, NA, Powers, SK, Shrager, JB Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans.. N Engl J Med. (2008). 358 1327–35 [Article] [PubMed]×
2.Powers, SK, Shanely, RA, Coombes, JS, Koesterer, TJ, McKenzie, M, Van Gammeren, D, Cicale, M, Dodd, SL Mechanical ventilation results in progressive contractile dysfunction in the diaphragm.. J Appl Physiol (1985). (2002). 92 1851–8 [PubMed]
2.Powers, SK, Shanely, RA, Coombes, JS, Koesterer, TJ, McKenzie, M, Van Gammeren, D, Cicale, M, Dodd, SL Mechanical ventilation results in progressive contractile dysfunction in the diaphragm.. J Appl Physiol (1985). (2002). 92 1851–8 [PubMed]×
3.Shanely, RA, Zergeroglu, MA, Lennon, SL, Sugiura, T, Yimlamai, T, Enns, D, Belcastro, A, Powers, SK Mechanical ventilation-induced diaphragmatic atrophy is associated with oxidative injury and increased proteolytic activity.. Am J Respir Crit Care Med. (2002). 166 1369–74 [Article] [PubMed]
3.Shanely, RA, Zergeroglu, MA, Lennon, SL, Sugiura, T, Yimlamai, T, Enns, D, Belcastro, A, Powers, SK Mechanical ventilation-induced diaphragmatic atrophy is associated with oxidative injury and increased proteolytic activity.. Am J Respir Crit Care Med. (2002). 166 1369–74 [Article] [PubMed]×
4.Laghi, F, Cattapan, SE, Jubran, A, Parthasarathy, S, Warshawsky, P, Choi, YS, Tobin, MJ Is weaning failure caused by low-frequency fatigue of the diaphragm?. Am J Respir Crit Care Med. (2003). 167 120–7 [Article] [PubMed]
4.Laghi, F, Cattapan, SE, Jubran, A, Parthasarathy, S, Warshawsky, P, Choi, YS, Tobin, MJ Is weaning failure caused by low-frequency fatigue of the diaphragm?. Am J Respir Crit Care Med. (2003). 167 120–7 [Article] [PubMed]×
5.Jubran, A Critical illness and mechanical ventilation: Effects on the diaphragm.. Respir Care. (2006). 51 1054–61; discussion 1062–4 [PubMed]
5.Jubran, A Critical illness and mechanical ventilation: Effects on the diaphragm.. Respir Care. (2006). 51 1054–61; discussion 1062–4 [PubMed]×
6.Shanely, RA, Van Gammeren, D, Deruisseau, KC, Zergeroglu, AM, McKenzie, MJ, Yarasheski, KE, Powers, SK Mechanical ventilation depresses protein synthesis in the rat diaphragm.. Am J Respir Crit Care Med. (2004). 170 994–9 [Article] [PubMed]
6.Shanely, RA, Van Gammeren, D, Deruisseau, KC, Zergeroglu, AM, McKenzie, MJ, Yarasheski, KE, Powers, SK Mechanical ventilation depresses protein synthesis in the rat diaphragm.. Am J Respir Crit Care Med. (2004). 170 994–9 [Article] [PubMed]×
7.Whidden, MA, Smuder, AJ, Wu, M, Hudson, MB, Nelson, WB, Powers, SK Oxidative stress is required for mechanical ventilation-induced protease activation in the diaphragm.. J Appl Physiol (1985). (2010). 108 1376–82 [Article] [PubMed]
7.Whidden, MA, Smuder, AJ, Wu, M, Hudson, MB, Nelson, WB, Powers, SK Oxidative stress is required for mechanical ventilation-induced protease activation in the diaphragm.. J Appl Physiol (1985). (2010). 108 1376–82 [Article] [PubMed]×
8.Hussain, SN, Mofarrahi, M, Sigala, I, Kim, HC, Vassilakopoulos, T, Maltais, F, Bellenis, I, Chaturvedi, R, Gottfried, SB, Metrakos, P, Danialou, G, Matecki, S, Jaber, S, Petrof, BJ, Goldberg, P Mechanical ventilation-induced diaphragm disuse in humans triggers autophagy.. Am J Respir Crit Care Med. (2010). 182 1377–86 [Article] [PubMed]
8.Hussain, SN, Mofarrahi, M, Sigala, I, Kim, HC, Vassilakopoulos, T, Maltais, F, Bellenis, I, Chaturvedi, R, Gottfried, SB, Metrakos, P, Danialou, G, Matecki, S, Jaber, S, Petrof, BJ, Goldberg, P Mechanical ventilation-induced diaphragm disuse in humans triggers autophagy.. Am J Respir Crit Care Med. (2010). 182 1377–86 [Article] [PubMed]×
9.McClung, JM, Kavazis, AN, DeRuisseau, KC, Falk, DJ, Deering, MA, Lee, Y, Sugiura, T, Powers, SK Caspase-3 regulation of diaphragm myonuclear domain during mechanical ventilation-induced atrophy.. Am J Respir Crit Care Med. (2007). 175 150–9 [Article] [PubMed]
9.McClung, JM, Kavazis, AN, DeRuisseau, KC, Falk, DJ, Deering, MA, Lee, Y, Sugiura, T, Powers, SK Caspase-3 regulation of diaphragm myonuclear domain during mechanical ventilation-induced atrophy.. Am J Respir Crit Care Med. (2007). 175 150–9 [Article] [PubMed]×
10.Maes, K, Testelmans, D, Powers, S, Decramer, M, Gayan-Ramirez, G Leupeptin inhibits ventilator-induced diaphragm dysfunction in rats.. Am J Respir Crit Care Med. (2007). 175 1134–8 [Article] [PubMed]
10.Maes, K, Testelmans, D, Powers, S, Decramer, M, Gayan-Ramirez, G Leupeptin inhibits ventilator-induced diaphragm dysfunction in rats.. Am J Respir Crit Care Med. (2007). 175 1134–8 [Article] [PubMed]×
11.Nelson, WB, Smuder, AJ, Hudson, MB, Talbert, EE, Powers, SK Cross-talk between the calpain and caspase-3 proteolytic systems in the diaphragm during prolonged mechanical ventilation.. Crit Care Med. (2012). 40 1857–63 [Article] [PubMed]
11.Nelson, WB, Smuder, AJ, Hudson, MB, Talbert, EE, Powers, SK Cross-talk between the calpain and caspase-3 proteolytic systems in the diaphragm during prolonged mechanical ventilation.. Crit Care Med. (2012). 40 1857–63 [Article] [PubMed]×
12.Krawiec, BJ, Frost, RA, Vary, TC, Jefferson, LS, Lang, CH Hindlimb casting decreases muscle mass in part by proteasome-dependent proteolysis but independent of protein synthesis.. Am J Physiol Endocrinol Metab. (2005). 289 E969–80 [Article] [PubMed]
12.Krawiec, BJ, Frost, RA, Vary, TC, Jefferson, LS, Lang, CH Hindlimb casting decreases muscle mass in part by proteasome-dependent proteolysis but independent of protein synthesis.. Am J Physiol Endocrinol Metab. (2005). 289 E969–80 [Article] [PubMed]×
13.Agten, A, Maes, K, Thomas, D, Cielen, N, Van Hees, HW, Dekhuijzen, RP, Decramer, M, Gayan-Ramirez, G Bortezomib partially protects the rat diaphragm from ventilator-induced diaphragm dysfunction.. Crit Care Med. (2012). 40 2449–55 [Article] [PubMed]
13.Agten, A, Maes, K, Thomas, D, Cielen, N, Van Hees, HW, Dekhuijzen, RP, Decramer, M, Gayan-Ramirez, G Bortezomib partially protects the rat diaphragm from ventilator-induced diaphragm dysfunction.. Crit Care Med. (2012). 40 2449–55 [Article] [PubMed]×
14.Supinski, GS, Vanags, J, Callahan, LA Effect of proteasome inhibitors on endotoxin-induced diaphragm dysfunction.. Am J Physiol Lung Cell Mol Physiol. (2009). 296 L994–1001 [Article] [PubMed]
14.Supinski, GS, Vanags, J, Callahan, LA Effect of proteasome inhibitors on endotoxin-induced diaphragm dysfunction.. Am J Physiol Lung Cell Mol Physiol. (2009). 296 L994–1001 [Article] [PubMed]×
15.Segal, SS, White, TP, Faulkner, JA Architecture, composition, and contractile properties of rat soleus muscle grafts.. Am J Physiol. (1986). 2503 Pt 1 C474–9 [PubMed]
15.Segal, SS, White, TP, Faulkner, JA Architecture, composition, and contractile properties of rat soleus muscle grafts.. Am J Physiol. (1986). 2503 Pt 1 C474–9 [PubMed]×
16.Reid, MB Free radicals and muscle fatigue: Of ROS, canaries, and the IOC.. Free Radic Biol Med. (2008). 44 169–79 [Article] [PubMed]
16.Reid, MB Free radicals and muscle fatigue: Of ROS, canaries, and the IOC.. Free Radic Biol Med. (2008). 44 169–79 [Article] [PubMed]×
17.McClung, JM, Whidden, MA, Kavazis, AN, Falk, DJ, Deruisseau, KC, Powers, SK Redox regulation of diaphragm proteolysis during mechanical ventilation.. Am J Physiol Regul Integr Comp Physiol. (2008). 294 R1608–17 [Article] [PubMed]
17.McClung, JM, Whidden, MA, Kavazis, AN, Falk, DJ, Deruisseau, KC, Powers, SK Redox regulation of diaphragm proteolysis during mechanical ventilation.. Am J Physiol Regul Integr Comp Physiol. (2008). 294 R1608–17 [Article] [PubMed]×
18.van der Westhuyzen, DR, Matsumoto, K, Etlinger, JD Easily releasable myofilaments from skeletal and cardiac muscles maintained in vitro. Role in myofibrillar assembly and turnover.. J Biol Chem. (1981). 256 11791–7 [PubMed]
18.van der Westhuyzen, DR, Matsumoto, K, Etlinger, JD Easily releasable myofilaments from skeletal and cardiac muscles maintained in vitro. Role in myofibrillar assembly and turnover.. J Biol Chem. (1981). 256 11791–7 [PubMed]×
19.Deruisseau, KC, Kavazis, AN, Powers, SK Selective downregulation of ubiquitin conjugation cascade mRNA occurs in the senescent rat soleus muscle.. Exp Gerontol. (2005). 40 526–31 [Article] [PubMed]
19.Deruisseau, KC, Kavazis, AN, Powers, SK Selective downregulation of ubiquitin conjugation cascade mRNA occurs in the senescent rat soleus muscle.. Exp Gerontol. (2005). 40 526–31 [Article] [PubMed]×
20.DeRuisseau, KC, Shanely, RA, Akunuri, N, Hamilton, MT, Van Gammeren, D, Zergeroglu, AM, McKenzie, M, Powers, SK Diaphragm unloading via controlled mechanical ventilation alters the gene expression profile.. Am J Respir Crit Care Med. (2005). 172 1267–75 [Article] [PubMed]
20.DeRuisseau, KC, Shanely, RA, Akunuri, N, Hamilton, MT, Van Gammeren, D, Zergeroglu, AM, McKenzie, M, Powers, SK Diaphragm unloading via controlled mechanical ventilation alters the gene expression profile.. Am J Respir Crit Care Med. (2005). 172 1267–75 [Article] [PubMed]×
21.Stein, RL, Melandri, F, Dick, L Kinetic characterization of the chymotryptic activity of the 20S proteasome.. Biochemistry. (1996). 35 3899–908 [Article] [PubMed]
21.Stein, RL, Melandri, F, Dick, L Kinetic characterization of the chymotryptic activity of the 20S proteasome.. Biochemistry. (1996). 35 3899–908 [Article] [PubMed]×
22.Powers, SK, Hudson, MB, Nelson, WB, Talbert, EE, Min, K, Szeto, HH, Kavazis, AN, Smuder, AJ Mitochondria-targeted antioxidants protect against mechanical ventilation-induced diaphragm weakness.. Crit Care Med. (2011). 39 1749–59 [Article] [PubMed]
22.Powers, SK, Hudson, MB, Nelson, WB, Talbert, EE, Min, K, Szeto, HH, Kavazis, AN, Smuder, AJ Mitochondria-targeted antioxidants protect against mechanical ventilation-induced diaphragm weakness.. Crit Care Med. (2011). 39 1749–59 [Article] [PubMed]×
23.Smuder, AJ, Hudson, MB, Nelson, WB, Kavazis, AN, Powers, SK Nuclear factor-κB signaling contributes to mechanical ventilation-induced diaphragm weakness*.. Crit Care Med. (2012). 40 927–34 [Article] [PubMed]
23.Smuder, AJ, Hudson, MB, Nelson, WB, Kavazis, AN, Powers, SK Nuclear factor-κB signaling contributes to mechanical ventilation-induced diaphragm weakness*.. Crit Care Med. (2012). 40 927–34 [Article] [PubMed]×
24.Betters, JL, Criswell, DS, Shanely, RA, Van Gammeren, D, Falk, D, Deruisseau, KC, Deering, M, Yimlamai, T, Powers, SK Trolox attenuates mechanical ventilation-induced diaphragmatic dysfunction and proteolysis.. Am J Respir Crit Care Med. (2004). 170 1179–84 [Article] [PubMed]
24.Betters, JL, Criswell, DS, Shanely, RA, Van Gammeren, D, Falk, D, Deruisseau, KC, Deering, M, Yimlamai, T, Powers, SK Trolox attenuates mechanical ventilation-induced diaphragmatic dysfunction and proteolysis.. Am J Respir Crit Care Med. (2004). 170 1179–84 [Article] [PubMed]×
25.Baehr, LM, Furlow, JD, Bodine, SC Muscle sparing in muscle RING finger 1 null mice: Response to synthetic glucocorticoids.. J Physiol. (2011). 589Pt 19 4759–76 [PubMed]
25.Baehr, LM, Furlow, JD, Bodine, SC Muscle sparing in muscle RING finger 1 null mice: Response to synthetic glucocorticoids.. J Physiol. (2011). 589Pt 19 4759–76 [PubMed]×
26.Bodine, SC, Latres, E, Baumhueter, S, Lai, VK, Nunez, L, Clarke, BA, Poueymirou, WT, Panaro, FJ, Na, E, Dharmarajan, K, Pan, ZQ, Valenzuela, DM, DeChiara, TM, Stitt, TN, Yancopoulos, GD, Glass, DJ Identification of ubiquitin ligases required for skeletal muscle atrophy.. Science. (2001). 294 1704–8 [Article] [PubMed]
26.Bodine, SC, Latres, E, Baumhueter, S, Lai, VK, Nunez, L, Clarke, BA, Poueymirou, WT, Panaro, FJ, Na, E, Dharmarajan, K, Pan, ZQ, Valenzuela, DM, DeChiara, TM, Stitt, TN, Yancopoulos, GD, Glass, DJ Identification of ubiquitin ligases required for skeletal muscle atrophy.. Science. (2001). 294 1704–8 [Article] [PubMed]×
27.Files, DC, D’Alessio, FR, Johnston, LF, Kesari, P, Aggarwal, NR, Garibaldi, BT, Mock, JR, Simmers, JL, DeGorordo, A, Murdoch, J, Willis, MS, Patterson, C, Tankersley, CG, Messi, ML, Liu, C, Delbono, O, Furlow, JD, Bodine, SC, Cohn, RD, King, LS, Crow, MT A critical role for muscle ring finger-1 in acute lung injury-associated skeletal muscle wasting.. Am J Respir Crit Care Med. (2012). 185 825–34 [Article] [PubMed]
27.Files, DC, D’Alessio, FR, Johnston, LF, Kesari, P, Aggarwal, NR, Garibaldi, BT, Mock, JR, Simmers, JL, DeGorordo, A, Murdoch, J, Willis, MS, Patterson, C, Tankersley, CG, Messi, ML, Liu, C, Delbono, O, Furlow, JD, Bodine, SC, Cohn, RD, King, LS, Crow, MT A critical role for muscle ring finger-1 in acute lung injury-associated skeletal muscle wasting.. Am J Respir Crit Care Med. (2012). 185 825–34 [Article] [PubMed]×
28.Powers, SK, Smuder, AJ, Criswell, DS Mechanistic links between oxidative stress and disuse muscle atrophy.. Antioxid Redox Signal. (2011). 15 2519–28 [Article] [PubMed]
28.Powers, SK, Smuder, AJ, Criswell, DS Mechanistic links between oxidative stress and disuse muscle atrophy.. Antioxid Redox Signal. (2011). 15 2519–28 [Article] [PubMed]×
29.Grune, T, Merker, K, Sandig, G, Davies, KJ Selective degradation of oxidatively modified protein substrates by the proteasome.. Biochem Biophys Res Commun. (2003). 305 709–18 [Article] [PubMed]
29.Grune, T, Merker, K, Sandig, G, Davies, KJ Selective degradation of oxidatively modified protein substrates by the proteasome.. Biochem Biophys Res Commun. (2003). 305 709–18 [Article] [PubMed]×
30.DeRuisseau, KC, Kavazis, AN, Deering, MA, Falk, DJ, Van Gammeren, D, Yimlamai, T, Ordway, GA, Powers, SK Mechanical ventilation induces alterations of the ubiquitin-proteasome pathway in the diaphragm.. J Appl Physiol (1985). (2005). 98 1314–21 [Article] [PubMed]
30.DeRuisseau, KC, Kavazis, AN, Deering, MA, Falk, DJ, Van Gammeren, D, Yimlamai, T, Ordway, GA, Powers, SK Mechanical ventilation induces alterations of the ubiquitin-proteasome pathway in the diaphragm.. J Appl Physiol (1985). (2005). 98 1314–21 [Article] [PubMed]×
31.Jagoe, RT, Goldberg, AL What do we really know about the ubiquitin-proteasome pathway in muscle atrophy?. Curr Opin Clin Nutr Metab Care. (2001). 4 183–90 [Article] [PubMed]
31.Jagoe, RT, Goldberg, AL What do we really know about the ubiquitin-proteasome pathway in muscle atrophy?. Curr Opin Clin Nutr Metab Care. (2001). 4 183–90 [Article] [PubMed]×
32.Smuder, AJ, Kavazis, AN, Hudson, MB, Nelson, WB, Powers, SK Oxidation enhances myofibrillar protein degradation via calpain and caspase-3.. Free Radic Biol Med. (2010). 49 1152–60 [Article] [PubMed]
32.Smuder, AJ, Kavazis, AN, Hudson, MB, Nelson, WB, Powers, SK Oxidation enhances myofibrillar protein degradation via calpain and caspase-3.. Free Radic Biol Med. (2010). 49 1152–60 [Article] [PubMed]×
33.Bader, N, Grune, T Protein oxidation and proteolysis.. Biol Chem. (2006). 387 1351–5 [Article] [PubMed]
33.Bader, N, Grune, T Protein oxidation and proteolysis.. Biol Chem. (2006). 387 1351–5 [Article] [PubMed]×
34.Smith, MA, Reid, MB Redox modulation of contractile function in respiratory and limb skeletal muscle.. Respir Physiol Neurobiol. (2006). 151 229–41 [Article] [PubMed]
34.Smith, MA, Reid, MB Redox modulation of contractile function in respiratory and limb skeletal muscle.. Respir Physiol Neurobiol. (2006). 151 229–41 [Article] [PubMed]×
35.Li, YP, Chen, Y, John, J, Moylan, J, Jin, B, Mann, DL, Reid, MB TNF-α acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle.. FASEB J. (2005). 19 362–70 [Article] [PubMed]
35.Li, YP, Chen, Y, John, J, Moylan, J, Jin, B, Mann, DL, Reid, MB TNF-α acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle.. FASEB J. (2005). 19 362–70 [Article] [PubMed]×
36.Li, YP, Chen, Y, Li, AS, Reid, MB Hydrogen peroxide stimulates ubiquitin-conjugating activity and expression of genes for specific E2 and E3 proteins in skeletal muscle myotubes.. Am J Physiol Cell Physiol. (2003). 285 C806–12 [Article] [PubMed]
36.Li, YP, Chen, Y, Li, AS, Reid, MB Hydrogen peroxide stimulates ubiquitin-conjugating activity and expression of genes for specific E2 and E3 proteins in skeletal muscle myotubes.. Am J Physiol Cell Physiol. (2003). 285 C806–12 [Article] [PubMed]×
37.McClung, JM, Judge, AR, Talbert, EE, Powers, SK Calpain-1 is required for hydrogen peroxide-induced myotube atrophy.. Am J Physiol Cell Physiol. (2009). 296 C363–71 [Article] [PubMed]
37.McClung, JM, Judge, AR, Talbert, EE, Powers, SK Calpain-1 is required for hydrogen peroxide-induced myotube atrophy.. Am J Physiol Cell Physiol. (2009). 296 C363–71 [Article] [PubMed]×
38.Falk, DJ, Deruisseau, KC, Van Gammeren, DL, Deering, MA, Kavazis, AN, Powers, SK Mechanical ventilation promotes redox status alterations in the diaphragm.. J Appl Physiol (1985). (2006). 101 1017–24 [Article] [PubMed]
38.Falk, DJ, Deruisseau, KC, Van Gammeren, DL, Deering, MA, Kavazis, AN, Powers, SK Mechanical ventilation promotes redox status alterations in the diaphragm.. J Appl Physiol (1985). (2006). 101 1017–24 [Article] [PubMed]×
39.Jackman, RW, Kandarian, SC The molecular basis of skeletal muscle atrophy.. Am J Physiol Cell Physiol. (2004). 287 C834–43 [Article] [PubMed]
39.Jackman, RW, Kandarian, SC The molecular basis of skeletal muscle atrophy.. Am J Physiol Cell Physiol. (2004). 287 C834–43 [Article] [PubMed]×
40.Powers, SK, Kavazis, AN, DeRuisseau, KC Mechanisms of disuse muscle atrophy: Role of oxidative stress.. Am J Physiol Regul Integr Comp Physiol. (2005). 288 R337–44 [Article] [PubMed]
40.Powers, SK, Kavazis, AN, DeRuisseau, KC Mechanisms of disuse muscle atrophy: Role of oxidative stress.. Am J Physiol Regul Integr Comp Physiol. (2005). 288 R337–44 [Article] [PubMed]×
41.Neti, G, Novak, SM, Thompson, VF, Goll, DE Properties of easily releasable myofilaments: Are they the first step in myofibrillar protein turnover?. Am J Physiol Cell Physiol. (2009). 296 C1383–90 [Article] [PubMed]
41.Neti, G, Novak, SM, Thompson, VF, Goll, DE Properties of easily releasable myofilaments: Are they the first step in myofibrillar protein turnover?. Am J Physiol Cell Physiol. (2009). 296 C1383–90 [Article] [PubMed]×
42.Furuno, K, Goodman, MN, Goldberg, AL Role of different proteolytic systems in the degradation of muscle proteins during denervation atrophy.. J Biol Chem. (1990). 265 8550–7 [PubMed]
42.Furuno, K, Goodman, MN, Goldberg, AL Role of different proteolytic systems in the degradation of muscle proteins during denervation atrophy.. J Biol Chem. (1990). 265 8550–7 [PubMed]×
43.Powers, SK, Kavazis, AN, McClung, JM Oxidative stress and disuse muscle atrophy.. J Appl Physiol (1985). (2007). 102 2389–97 [Article] [PubMed]
43.Powers, SK, Kavazis, AN, McClung, JM Oxidative stress and disuse muscle atrophy.. J Appl Physiol (1985). (2007). 102 2389–97 [Article] [PubMed]×
44.Reid, MB Response of the ubiquitin-proteasome pathway to changes in muscle activity.. Am J Physiol Regul Integr Comp Physiol. (2005). 288 R1423–31 [Article] [PubMed]
44.Reid, MB Response of the ubiquitin-proteasome pathway to changes in muscle activity.. Am J Physiol Regul Integr Comp Physiol. (2005). 288 R1423–31 [Article] [PubMed]×
45.Goll, DE, Thompson, VF, Li, H, Wei, W, Cong, J The calpain system.. Physiol Rev. (2003). 83 731–801 [PubMed]
45.Goll, DE, Thompson, VF, Li, H, Wei, W, Cong, J The calpain system.. Physiol Rev. (2003). 83 731–801 [PubMed]×
46.Lecker, SH, Solomon, V, Mitch, WE, Goldberg, AL Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states.. J Nutr. (1999). 1291S suppl 227–37S
46.Lecker, SH, Solomon, V, Mitch, WE, Goldberg, AL Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states.. J Nutr. (1999). 1291S suppl 227–37S×
47.Mitch, WE, Goldberg, AL Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway.. N Engl J Med. (1996). 335 1897–905 [Article] [PubMed]
47.Mitch, WE, Goldberg, AL Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway.. N Engl J Med. (1996). 335 1897–905 [Article] [PubMed]×
48.Solomon, V, Goldberg, AL Importance of the ATP-ubiquitin-proteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts.. J Biol Chem. (1996). 271 26690–7 [Article] [PubMed]
48.Solomon, V, Goldberg, AL Importance of the ATP-ubiquitin-proteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts.. J Biol Chem. (1996). 271 26690–7 [Article] [PubMed]×
49.Tidball, JG, Spencer, MJ Expression of a calpastatin transgene slows muscle wasting and obviates changes in myosin isoform expression during murine muscle disuse.. J Physiol. (2002). 545Pt 3 819–28 [Article] [PubMed]
49.Tidball, JG, Spencer, MJ Expression of a calpastatin transgene slows muscle wasting and obviates changes in myosin isoform expression during murine muscle disuse.. J Physiol. (2002). 545Pt 3 819–28 [Article] [PubMed]×
50.Du, J, Wang, X, Miereles, C, Bailey, JL, Debigare, R, Zheng, B, Price, SR, Mitch, WE Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions.. J Clin Invest. (2004). 113 115–23 [Article] [PubMed]
50.Du, J, Wang, X, Miereles, C, Bailey, JL, Debigare, R, Zheng, B, Price, SR, Mitch, WE Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions.. J Clin Invest. (2004). 113 115–23 [Article] [PubMed]×
51.Zergeroglu, MA, McKenzie, MJ, Shanely, RA, Van Gammeren, D, DeRuisseau, KC, Powers, SK Mechanical ventilation-induced oxidative stress in the diaphragm.. J Appl Physiol (1985). (2003). 95 1116–24 [PubMed]
51.Zergeroglu, MA, McKenzie, MJ, Shanely, RA, Van Gammeren, D, DeRuisseau, KC, Powers, SK Mechanical ventilation-induced oxidative stress in the diaphragm.. J Appl Physiol (1985). (2003). 95 1116–24 [PubMed]×
Fig. 1.
Diaphragmatic force–frequency response (in vitro). Values are mean ± SD (n = 8 per group). CON significantly different versus mechanical ventilation (MV) (P < 0.001); CON significantly different versus MV + epoxomicin (P < 0.001); MV significantly different versus MV + epoxomicin (P = 0.007). Acutely anesthetized control animals (CON); 12-h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
Image Not Available
Fig. 1.
Diaphragmatic force–frequency response (in vitro). Values are mean ± SD (n = 8 per group). CON significantly different versus mechanical ventilation (MV) (P < 0.001); CON significantly different versus MV + epoxomicin (P < 0.001); MV significantly different versus MV + epoxomicin (P = 0.007). Acutely anesthetized control animals (CON); 12-h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
×
Fig. 2.
Fiber cross-sectional area in diaphragm skeletal muscle myofibers expressing myosin heavy chain (MHC) I (type I), MHC IIa (type IIa), and MHC IIx/IIb (type IIx/IIb) (CON: n = 7; MV: n = 8; MV + epoxomicin: n = 8). Values are mean ± SD. *Significantly different versus CON (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12-h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
Image Not Available
Fig. 2.
Fiber cross-sectional area in diaphragm skeletal muscle myofibers expressing myosin heavy chain (MHC) I (type I), MHC IIa (type IIa), and MHC IIx/IIb (type IIx/IIb) (CON: n = 7; MV: n = 8; MV + epoxomicin: n = 8). Values are mean ± SD. *Significantly different versus CON (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12-h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
×
Fig. 3.
The levels of 4-hydroxynonenal (4-HNE). A representative blot for 4-HNE protein conjugates is shown above the graph. Values are mean percentage change ± SD (n = 8 per group). *Significantly different versus CON (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
Image Not Available
Fig. 3.
The levels of 4-hydroxynonenal (4-HNE). A representative blot for 4-HNE protein conjugates is shown above the graph. Values are mean percentage change ± SD (n = 8 per group). *Significantly different versus CON (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
×
Fig. 4.
Easily releasable myofilaments (CON: n = 7; MV: n = 8; MV + epoxomicin: n = 7). Values are mean percentage change ± SD. *Significantly different versus CON (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
Image Not Available
Fig. 4.
Easily releasable myofilaments (CON: n = 7; MV: n = 8; MV + epoxomicin: n = 7). Values are mean percentage change ± SD. *Significantly different versus CON (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
×
Fig. 5.
(A) microRNA (mRNA) levels of muscle ring finger-1 (MuRF1) (CON: n = 8; MV: n = 7; MV + epoxomicin: n = 7). (B) mRNA levels of atrogin-1/Muscle Atrophy F-box (MaFbx) (CON: n = 8; MV: n = 8; MV + epoxomicin: n = 7). (C) Protein levels for MuRF1 (CON: n = 8; MV: n = 7; MV + epoxomicin: n = 8). (D) Protein levels for atrogin-1/MaFbx (n = 8 per group). Representative blots for MuRF1 and atrogin-1/MaFbx protein are shown above the graph. Values are mean percentage change ± SD. *Significantly different versus CON (P < 0.0167). §Significantly different versus CON and MV + epoxomicin (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
Image Not Available
Fig. 5.
(A) microRNA (mRNA) levels of muscle ring finger-1 (MuRF1) (CON: n = 8; MV: n = 7; MV + epoxomicin: n = 7). (B) mRNA levels of atrogin-1/Muscle Atrophy F-box (MaFbx) (CON: n = 8; MV: n = 8; MV + epoxomicin: n = 7). (C) Protein levels for MuRF1 (CON: n = 8; MV: n = 7; MV + epoxomicin: n = 8). (D) Protein levels for atrogin-1/MaFbx (n = 8 per group). Representative blots for MuRF1 and atrogin-1/MaFbx protein are shown above the graph. Values are mean percentage change ± SD. *Significantly different versus CON (P < 0.0167). §Significantly different versus CON and MV + epoxomicin (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
×
Fig. 6.
(A) Protein levels for poly-ubiquitinated protein (pUB) (n = 8 per group). (B) Chymotrypsin-like activity of the 20S ubiquitin–proteasome system (n = 7 per group). Representative blots for pUB protein are shown above the graph. Values are mean percentage change ± SD. *Significantly different versus CON (P < 0.0167). §Significantly different versus CON and MV + epoxomicin (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
Image Not Available
Fig. 6.
(A) Protein levels for poly-ubiquitinated protein (pUB) (n = 8 per group). (B) Chymotrypsin-like activity of the 20S ubiquitin–proteasome system (n = 7 per group). Representative blots for pUB protein are shown above the graph. Values are mean percentage change ± SD. *Significantly different versus CON (P < 0.0167). §Significantly different versus CON and MV + epoxomicin (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
×
Fig. 7.
Calpain activation in the diaphragm was determined via Western blot. (A) Active calpain-1 (n = 8 per group). (B) Calpain-specific spectrin breakdown product (SBDP) (n = 8 per group). Representative Western blots are shown above the graphs. Values are mean percentage change ± SD. *Significantly different versus CON (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
Image Not Available
Fig. 7.
Calpain activation in the diaphragm was determined via Western blot. (A) Active calpain-1 (n = 8 per group). (B) Calpain-specific spectrin breakdown product (SBDP) (n = 8 per group). Representative Western blots are shown above the graphs. Values are mean percentage change ± SD. *Significantly different versus CON (P < 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
×
Fig. 8.
Caspase-3 activation in the diaphragm was determined via Western blot. (A) Cleaved (active) caspase-3 (CON: n = 8; MV: n = 6; MV + epoxomicin: n = 6). (B) Caspase-3-specific spectrin breakdown product (SBDP) (n = 8 per group). Representative Western blots are shown above the graphs. Values are mean percentage change ± SD. *Significantly different versus CON (P< 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
Image Not Available
Fig. 8.
Caspase-3 activation in the diaphragm was determined via Western blot. (A) Cleaved (active) caspase-3 (CON: n = 8; MV: n = 6; MV + epoxomicin: n = 6). (B) Caspase-3-specific spectrin breakdown product (SBDP) (n = 8 per group). Representative Western blots are shown above the graphs. Values are mean percentage change ± SD. *Significantly different versus CON (P< 0.0167). Exact P values for all comparisons are listed below the graph. Acutely anesthetized control animals (CON); 12 h mechanically ventilated animals, no treatment (MV); 12 h of MV, treatment with the proteasome inhibitor epoxomicin (MV + epoxomicin).
×
Table 1.
Effects of DMSO Administration on Diaphragm Contractile Function
Effects of DMSO Administration on Diaphragm Contractile Function×
Image Not Available
Table 1.
Effects of DMSO Administration on Diaphragm Contractile Function
Effects of DMSO Administration on Diaphragm Contractile Function×
×
Table 2.
Systemic and Biological Response to MV
Systemic and Biological Response to MV×
Image Not Available
Table 2.
Systemic and Biological Response to MV
Systemic and Biological Response to MV×
×